Ten years surveillance of antimicrobial susceptibility of community-acquired Escherichia coli and Other uropathogens in Northern Israel (1995-2005)

Israel Medical Association Journal

Volumn 9, Issue 11, 2007, Pages 803-805

  Rock, Wasseem ^a   Colodner, Raul ^a   Chazan, Bibiana ^a   Elias, Mazen ^a   Raz, Raul ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antibiotic consumption; Antimicrobial resistance; Empiric antimicrobial therapy; Fluroquinolone resistant E. coll; Urinary tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFALOTIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; ISRAEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; URINARY TRACT INFECTION;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-INFECTIVE AGENTS, URINARY; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GRAM-NEGATIVE BACTERIA; HUMANS; ISRAEL; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; POPULATION SURVEILLANCE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; URINARY TRACT INFECTIONS;

EID: 36749099390     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Brown PD. Antibiotic selection for urinary tract infection: new microbiologic considerations. Curr Infect Dis Rep 1999;1:381-8.
2. Gupta K. Addressing antibiotic resistance. Am J Med 2002;8(Suppl IA):29-34S.
3. Chazan B, Sakran W, Raz R, Colodner R. Improved antimicrobial susceptibility of community-acquired uropathogens in northern Israel (1995-1999-2002). Int J Antimicrob Agents 2004;2489-92.
4. Clarridge JE, Johnson JR, Pezzlo AM, Laboratory Diagnosis of Urinary Tract Infections, Cumitech 2B. Washington DC: ASM Press, 1998.
5. National Committee for Clinical Laboratory Standards (CLSI). Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement, M100-S11. Wayne, CLSI, 2001.
6. Raz R, Okev N, Kennes Y, Gilboa A, Lavi I, Bisharat N. Demographic characteristics of patients with community-acquired bacteriuria and susceptibility of urinary pathogens to antimicrobials in northern Israel. IMAJ 2000;2:426-9.
7. Karaca Y, Coplu N, Gozalan A, Oncul O, Citil BE, Esen B. Co-trimoxazole and quinolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years. Int J Antimicrob Agents 2005;26 75-7.
8. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO-SENS study. Int J Antimicrob Agents 2003,2 (Suppl 2):49-52.
9. Eom JS, Hwang BY, Sohn JW, Kim MJ, Park SC, Cheong HJ. Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection. Microb Drug Resist 2002;8:227-34.
10. Killgore KM, March KL, Guglielmo BJ, Risk factors for community acquired ciprofloxacin-resistant Escherechia coli urinary tract infection. Ann Pharmacother 2004;38:1148-52.